Bromide

Bromide

SCHEMBL1729360

Br.COc1ccc2c(c1)C(=N)N(CC(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)C2

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
MAPT P10636 2/20 0.58
RAB9A P51151 2/20 0.58
NPC1 O15118 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.43
F2R P25116 16/20 0.43
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5490576 0.92 KDM4E (0.58) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL1731234 0.91 KDM4E (0.56) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1730560 0.90 KDM4E (0.48) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1729189 0.90 KDM4E (0.48) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1731700 0.89 KDM4E (0.48) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1730861 0.89 KDM4E (0.48) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL5484091 0.88 KDM4E (0.47) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1728986 0.88 KDM4E (0.47) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1729208 0.88 KDM4E (0.47) KDM4EMAPTRAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1729171 0.88 KDM4E (0.46) KDM4EMAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 KDM4E 3161/4885MAPT 3483/4885RAB9A 429/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 KDM4E 3132/4885MAPT 3440/4885RAB9A 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.